January 2026
Ibogaine
What January 2026's 4 new studies found, synthesized from the papers below. All Ibogaine research →
The synthesis
Synthesized from 4 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Ibogaine, iboga, noribogaine, then ranked by relevance.
Research on ibogaine in January 2026 shows mixed findings: it may offer rapid clinical improvements for neuropsychiatric disorders like TBI and PTSD in veterans and show potential for Parkinson's disease, but it also carries a rare but serious risk of cardiotoxicity (QTc prolongation and ventricular arrhythmias). Additionally, there is concern that promoting ibogaine for opioid use disorder could lead patients to discontinue proven, mortality-reducing medications, increasing overdose risk. The evidence is limited by small, open-label studies and case reports, with no large controlled trials.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Accelerated recovery using magnesium ibogaine: characterizing the subjective experience of its rapid healing from neuropsychiatric disorders. 2026 | open-label qualitative study | 30 | Supports | Magnesium-ibogaine treatment was associated with rapid clinical improvements and a subjective experience of dialogic trauma re-appraisal, mystical connectedness, emotional resolution, and embodied healing. |
| Rare but relevant: Ibogaine and cardiovascular complications-prolonged QT interval and ventricular arrhythmias. 2026 | review | Mixed | Ibogaine reduces craving and withdrawal in opioid/cocaine dependence but presents a rare risk of QTc prolongation and ventricular arrhythmias, even at therapeutic doses and in those without pre-existing cardiac conditions. | |
| Ibogaine for Opioid Use Disorder: An Unrecognized Risk. 2026 | commentary | Opposes | Framing ibogaine as an alternative to standard medications for opioid use disorder could lead to increased overdose risk if patients discontinue methadone or buprenorphine for an unproven therapy. | |
| Ibogaine for the treatment of Parkinson's disease: A case report 2026 | case report | 1 | Supports | Low-dose ibogaine hydrochloride over 80 days led to substantial improvements in motor symptoms, quality of life, fatigue, and depression, though sleep quality declined. |
Magnesium-ibogaine treatment was associated with rapid clinical improvements and a subjective experience of dialogic trauma re-appraisal, mystical connectedness, emotional resolution, and embodied healing.
open-label qualitative study Sample size: 30
Ibogaine reduces craving and withdrawal in opioid/cocaine dependence but presents a rare risk of QTc prolongation and ventricular arrhythmias, even at therapeutic doses and in those without pre-existing cardiac conditions.
review
Framing ibogaine as an alternative to standard medications for opioid use disorder could lead to increased overdose risk if patients discontinue methadone or buprenorphine for an unproven therapy.
commentary
Low-dose ibogaine hydrochloride over 80 days led to substantial improvements in motor symptoms, quality of life, fatigue, and depression, though sleep quality declined.
case report Sample size: 1
Points of agreement
- Ibogaine shows potential therapeutic benefits for neuropsychiatric conditions including addiction, TBI/PTSD, and Parkinson's disease.
- Cardiotoxicity (QTc prolongation, arrhythmias) is a consistent concern across studies.
Conflicts
- One study reports rapid healing and positive subjective experiences, while another warns that promoting ibogaine for opioid use disorder may undermine evidence-based treatments and increase overdose risk.
- The Parkinson's case report shows improved sleep quality declined, contrasting with overall positive effects.
Gaps
- No large, randomized controlled trials are available; evidence is from open-label, qualitative, or case studies.
- Durability of effects beyond short-term follow-up is not assessed.
- Cardiovascular safety in diverse populations and with standardized dosing protocols remains unstudied.
- Comparative effectiveness against standard treatments for opioid use disorder or Parkinson's disease is lacking.